Drug – bio-affecting and body treating compositions – Designated organic active ingredient containing – Peptide containing doai
Patent
1997-05-16
1999-02-23
Raymond, Richard L.
Drug, bio-affecting and body treating compositions
Designated organic active ingredient containing
Peptide containing doai
42419511, 424450, 424484, 424485, 424458, 514 3, 514183, 514283, 514781, 514782, 514801, 514802, 514946, 514947, A61K 3800, A61K 31435
Patent
active
058744029
ABSTRACT:
Methods are provided for the treatment of a host suffering from a cellular proliferative disease through administration of a chemotherapeutic agent in conjunction with a cell membrane permeant. Optionally, the cell membrane permeant and/or chemotherapeutic agent will be present in a pharmaceutically acceptable vehicle capable of acting as a depot. In the subject methods, the chemotherapeutic agent and membrane permeant are administered at least proximal to a target site of the host. Administration of chemotherapeutic agents in accordance with the subject methods results in improved efficacy of, and/or decreased host toxicity to, the intralesionally administered chemotherapeutic agent.
REFERENCES:
patent: Re33375 (1990-10-01), Luck et al.
patent: 5273965 (1993-12-01), Kensil et al.
Jekunen et al., "Modulation of Cisplatin Cytotoxicity by Permeabilization of the Plasma Membrane by Digitonin in vitro," Biochemical Pharmacology, 45:2079-2085 (1993).
Brown Dennis M.
Jones Richard E.
Singh Saira
Matrix Pharmaceutical, Inc.
Raymond Richard L.
LandOfFree
Use of cell membrane permeants in the treatment of cellular prol does not yet have a rating. At this time, there are no reviews or comments for this patent.
If you have personal experience with Use of cell membrane permeants in the treatment of cellular prol, we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and Use of cell membrane permeants in the treatment of cellular prol will most certainly appreciate the feedback.
Profile ID: LFUS-PAI-O-306898